PT3694863T - Forma cristalina do hidrato de base livre de lorlatinib - Google Patents
Forma cristalina do hidrato de base livre de lorlatinibInfo
- Publication number
- PT3694863T PT3694863T PT187958079T PT18795807T PT3694863T PT 3694863 T PT3694863 T PT 3694863T PT 187958079 T PT187958079 T PT 187958079T PT 18795807 T PT18795807 T PT 18795807T PT 3694863 T PT3694863 T PT 3694863T
- Authority
- PT
- Portugal
- Prior art keywords
- free base
- crystalline form
- base hydrate
- lorlatinib free
- lorlatinib
- Prior art date
Links
- 239000012458 free base Substances 0.000 title 1
- IIXWYSCJSQVBQM-LLVKDONJSA-N lorlatinib Chemical compound N=1N(C)C(C#N)=C2C=1CN(C)C(=O)C1=CC=C(F)C=C1[C@@H](C)OC1=CC2=CN=C1N IIXWYSCJSQVBQM-LLVKDONJSA-N 0.000 title 1
- 229950001290 lorlatinib Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570326P | 2017-10-10 | 2017-10-10 | |
| US201862727734P | 2018-09-06 | 2018-09-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3694863T true PT3694863T (pt) | 2023-08-23 |
Family
ID=64049474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT187958079T PT3694863T (pt) | 2017-10-10 | 2018-10-04 | Forma cristalina do hidrato de base livre de lorlatinib |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11299500B2 (enExample) |
| EP (1) | EP3694863B1 (enExample) |
| JP (1) | JP7153069B2 (enExample) |
| KR (1) | KR102424621B1 (enExample) |
| CN (1) | CN111201235B (enExample) |
| AU (1) | AU2018349259B2 (enExample) |
| CA (1) | CA3077508C (enExample) |
| CY (1) | CY1126141T1 (enExample) |
| DK (1) | DK3694863T3 (enExample) |
| ES (1) | ES2952985T3 (enExample) |
| FI (1) | FI3694863T3 (enExample) |
| HU (1) | HUE062926T2 (enExample) |
| MX (1) | MX2020003373A (enExample) |
| PL (1) | PL3694863T3 (enExample) |
| PT (1) | PT3694863T (enExample) |
| RU (1) | RU2022109286A (enExample) |
| SG (1) | SG11202002445SA (enExample) |
| SI (1) | SI3694863T1 (enExample) |
| TW (1) | TWI775960B (enExample) |
| WO (1) | WO2019073347A1 (enExample) |
| ZA (1) | ZA202001661B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3798222T3 (fi) | 2015-07-31 | 2023-11-28 | Pfizer | Lorlatinibin vapaan emäksen kidemuoto |
| ES2819676T3 (es) | 2016-04-08 | 2021-04-19 | Pfizer | Formas cristalinas de maleato de lorlatinib |
| WO2019209633A1 (en) * | 2018-04-23 | 2019-10-31 | Pliva Hrvatska D.O.O. | Solid state forms of lorlatinib and their preparation |
| EP3999514A1 (en) | 2019-07-18 | 2022-05-25 | Pliva Hrvatska D.O.O. | Crystalline lorlatinib : fumaric acid and solid state form thereof |
| CN112321604A (zh) * | 2019-08-05 | 2021-02-05 | 华东理工大学 | 大环类jak2抑制剂及其应用 |
| EP4041396A1 (en) | 2019-10-10 | 2022-08-17 | Sandoz AG | Polymorph of lorlatinib |
| CN112824417A (zh) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | 一种劳拉替尼的制备方法 |
| WO2021176349A1 (en) | 2020-03-05 | 2021-09-10 | Pfizer Inc. | Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor |
| CN111362967B (zh) * | 2020-04-28 | 2021-09-07 | 南京雷正医药科技有限公司 | 苯并氧杂二氮杂十四碳烯衍生物及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8916593B2 (en) | 2010-05-04 | 2014-12-23 | Pfizer Inc. | Alkoxy-substituted 2-aminopyridines as ALK inhibitors |
| WO2012121764A1 (en) | 2010-11-25 | 2012-09-13 | Ratiopharm Gmbh | Novel salts and polymorphic forms of afatinib |
| MX355421B (es) | 2011-06-08 | 2018-04-18 | Biogen Ma Inc | Proceso para preparar fumarato de dimetilo cristalino y de alta pureza. |
| WO2013132376A1 (en) | 2012-03-06 | 2013-09-12 | Pfizer Inc. | Macrocyclic derivatives for the treatment of proliferative diseases |
| ES2656189T3 (es) * | 2013-06-28 | 2018-02-26 | Pfizer Inc. | Formas sólidas de un inhibidor macrocíclico de quinasa |
| WO2016026423A1 (en) * | 2014-08-20 | 2016-02-25 | Teligene Ltd | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
| EP3183256A4 (en) * | 2014-08-20 | 2018-05-30 | Teligene Ltd. | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
| FI3798222T3 (fi) | 2015-07-31 | 2023-11-28 | Pfizer | Lorlatinibin vapaan emäksen kidemuoto |
| ES2819676T3 (es) | 2016-04-08 | 2021-04-19 | Pfizer | Formas cristalinas de maleato de lorlatinib |
-
2018
- 2018-10-04 KR KR1020207010512A patent/KR102424621B1/ko active Active
- 2018-10-04 SI SI201830952T patent/SI3694863T1/sl unknown
- 2018-10-04 US US16/650,505 patent/US11299500B2/en active Active
- 2018-10-04 SG SG11202002445SA patent/SG11202002445SA/en unknown
- 2018-10-04 DK DK18795807.9T patent/DK3694863T3/da active
- 2018-10-04 ES ES18795807T patent/ES2952985T3/es active Active
- 2018-10-04 MX MX2020003373A patent/MX2020003373A/es unknown
- 2018-10-04 WO PCT/IB2018/057735 patent/WO2019073347A1/en not_active Ceased
- 2018-10-04 JP JP2020520115A patent/JP7153069B2/ja active Active
- 2018-10-04 EP EP18795807.9A patent/EP3694863B1/en active Active
- 2018-10-04 CA CA3077508A patent/CA3077508C/en active Active
- 2018-10-04 AU AU2018349259A patent/AU2018349259B2/en active Active
- 2018-10-04 CN CN201880065709.6A patent/CN111201235B/zh active Active
- 2018-10-04 FI FIEP18795807.9T patent/FI3694863T3/fi active
- 2018-10-04 RU RU2022109286A patent/RU2022109286A/ru unknown
- 2018-10-04 PL PL18795807.9T patent/PL3694863T3/pl unknown
- 2018-10-04 HU HUE18795807A patent/HUE062926T2/hu unknown
- 2018-10-04 PT PT187958079T patent/PT3694863T/pt unknown
- 2018-10-05 TW TW107135186A patent/TWI775960B/zh active
-
2020
- 2020-03-17 ZA ZA2020/01661A patent/ZA202001661B/en unknown
-
2023
- 2023-07-25 CY CY20231100357T patent/CY1126141T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020113141A3 (enExample) | 2021-11-12 |
| JP7153069B2 (ja) | 2022-10-13 |
| MX2020003373A (es) | 2020-10-12 |
| TWI775960B (zh) | 2022-09-01 |
| BR112020005989A2 (pt) | 2020-09-29 |
| EP3694863A1 (en) | 2020-08-19 |
| ES2952985T3 (es) | 2023-11-07 |
| CY1126141T1 (el) | 2023-11-15 |
| CN111201235A (zh) | 2020-05-26 |
| US20200308191A1 (en) | 2020-10-01 |
| CA3077508A1 (en) | 2019-04-18 |
| JP2020536893A (ja) | 2020-12-17 |
| AU2018349259A1 (en) | 2020-04-09 |
| RU2022109286A (ru) | 2022-05-06 |
| AU2018349259B2 (en) | 2021-02-18 |
| HUE062926T2 (hu) | 2023-12-28 |
| SI3694863T1 (sl) | 2023-10-30 |
| RU2020113141A (ru) | 2021-11-12 |
| EP3694863B1 (en) | 2023-06-21 |
| CN111201235B (zh) | 2023-02-10 |
| FI3694863T3 (fi) | 2023-08-18 |
| CA3077508C (en) | 2023-02-14 |
| TW201922753A (zh) | 2019-06-16 |
| KR20200051781A (ko) | 2020-05-13 |
| WO2019073347A1 (en) | 2019-04-18 |
| DK3694863T3 (da) | 2023-07-03 |
| US11299500B2 (en) | 2022-04-12 |
| KR102424621B1 (ko) | 2022-07-25 |
| ZA202001661B (en) | 2023-11-29 |
| SG11202002445SA (en) | 2020-04-29 |
| PL3694863T3 (pl) | 2023-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288519B1 (en) | inhibitors of ret | |
| SG11202002445SA (en) | Crystalline form of lorlatinib free base hydrate | |
| SG10201913200XA (en) | Crystalline form of lorlatinib free base | |
| SG10202111790YA (en) | Synthesis of omecamtiv mecarbil | |
| PL3577125T3 (pl) | Postacie krystaliczne alafenamidu tenofowiru | |
| IL272697A (en) | A polymorphic form of TG02 | |
| SI3380554T1 (sl) | Kristalne oblike per-kloro-gama-ciklodekstrinov | |
| GB201614939D0 (en) | Crystalline hydrate | |
| SG10202101979TA (en) | Crystalline forms of c21h22ci2n4o2 | |
| PL3532457T3 (pl) | Postacie krystaliczne hydroksynorketaminy | |
| PL3529236T3 (pl) | Krystaliczne formy erawacykliny | |
| ZA201906464B (en) | Crystalline forms of (s)-afoxolaner | |
| IL269073A (en) | Crystalline forms of obeticholic acid | |
| IL270961A (en) | Crystalline form of N-butyldeoxygalactonogirimycin | |
| IL253479A0 (en) | Crystalline forms of efinconazole | |
| HK40092368A (zh) | 劳拉替尼游离碱的结晶形式 | |
| HK40093795A (zh) | 劳拉替尼游离碱的结晶形式 | |
| IL270937A (en) | Crystalline forms of saltalicib |